Renaissance Technologies’s DiaMedica Therapeutics DMAC Stock Holding History

Renaissance Technologies’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-52,523	Closed	-$356K	–	3288
2026 Q1	$356K	Buy	+52,523	New	+$416K	﹤0.01%	2746
2023 Q2	–	Sell	-64,508	Closed	-$99K	–	3995
2023 Q1	$99K	Buy	64,508 +30,889	+92%	+$49K	﹤0.01%	3495
2022 Q4	$53K	Buy	+33,619	New	+$45.3K	﹤0.01%	3786
2021 Q3	–	Sell	-94,100	Closed	-$419K	–	3540
2021 Q2	$419K	Sell	94,100 -59,000	-39%	-$484K	﹤0.01%	3031
2021 Q1	$1.4M	Buy	153,100 +39,700	+35%	+$371K	﹤0.01%	2436
2020 Q4	$1.15M	Buy	113,400 +17,400	+18%	+$95.2K	﹤0.01%	2428
2020 Q3	$407K	Sell	96,000 -8,700	-8%	-$46K	﹤0.01%	2893
2020 Q2	$726K	Buy	104,700 +78,851	+305%	+$352K	﹤0.01%	2710
2020 Q1	$72K	Buy	+25,849	New	+$107K	﹤0.01%	3281

Other funds holding DMAC

CLG

Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Renaissance Technologies's DMAC Position: Q2 2026 in Review

Renaissance Technologies sold out of DiaMedica Therapeutics (DMAC) in Q2 2026, closing a stake of 52,523 shares — an estimated $356K sold.

Renaissance Technologies first reported a position in DMAC in Q1 2020 and held it in 9 quarters. The position peaked at $1.4M in Q1 2021. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

Renaissance Technologies reported no remaining DiaMedica Therapeutics position as of Q2 2026 after selling out during the quarter.
Renaissance Technologies sold 52,523 DiaMedica Therapeutics shares in Q2 2026, an estimated $356K.
Renaissance Technologies first reported a position in DiaMedica Therapeutics in Q1 2020 and held it in 9 quarters.
Renaissance Technologies's DiaMedica Therapeutics position peaked at $1.4M in Q1 2021.
89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.